MedTrace Logo

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

NCT06755684 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-01-06

No results posted yet for this study

Summary

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Conditions

  • EGFR
  • Non-Small Cell Lung Cancer
  • Locally Advanced Non-Small Cell Lung Cancer
  • Pemetrexed
  • Carboplatin
  • Bevacizumab
  • Antineoplastic Agents
  • Tyrosine Kinase Inhibitor

Interventions

DRUG

Befotertinib combined Bevacizumab

Befotertinib combined Bevacizumab

DRUG

Befotertinib combined platinum-based double chemotherapy

Befotertinib combined platinum-based double chemotherapy

Sponsors & Collaborators

  • Peng Zhang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-07
Primary Completion
2025-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06755684 on ClinicalTrials.gov